Stay Connected
Atlanta Black Star/Health & Wellness
Health & Wellness

New Study: Aspirin Therapy May Benefit Those with Certain Cancers

Posted byBy Stan | Published on: | Updated on June 13, 2013 CommentsComments (0)

According to a report published in the October 25 edition of the New England Journal of Medicine, colorectal cancer patients whose tumors carry a specific mutation in a key gene may benefit from aspirin therapy.

In a study written and conducted by the Dana-Farber Cancer Institute, involving more than 900 colorectal cancer patients, researchers found that those patients whose tumors harbored the gene PIK3CA responded to aspirin therapy. Five years after diagnosis, 97 percent of those patients taking aspirin had survived, in comparison to 74 percent not taking aspirin. Aspirin therapy provided no benefit for those patients whose tumors did not contain a PIK3CA mutation. The Dana-Farber Cancer Institute reports that aspirin theory has no impact on patients who lack the gene mutation.

According to the Centers for Disease Control and Prevention, colorectal cancer is the second leading cause of cancer-related deaths in the United States. The CDC notes that in 2008, 52,857 people in the United States died because of colorectal cancer.

“Our results suggest that aspirin can be particularly effective in prolonging survival among patients whose colorectal cancer tests positive for a mutation in PIK3CA,” said the study’s senior author, Shuji Ogino, MD, PhD, of Dana-Farber, Brigham and Women’s Hospital, and the Harvard School of Public Health. “For the first time, we have a genetic marker that can help doctors determine which colorectal cancers are likely to respond to a particular therapy.”

Although further study is necessary before the results can be considered definitive, as Dr. Ogino cautions, aspirin has often been prescribed for colorectal cancer patients in spite of the difficulty in predicting which patients it will benefit. The findings of this study provide that information, suggesting that only the 20 percent of all patients whose tumors bear the important PIK3CA mutation will benefit from aspirin therapy…

Read more: National Monitor

 

Still independent.

We hope this story was worth your time. For over 14 years, Atlanta Black Star has stayed Black-owned and independently run. We didn't get here by waiting on ad budgets that were never built to prioritize us. Our readers did that.

Corporate support for Black media has always been thin. Outlets like ours get roughly 1% of the $170 billion spent on U.S. advertising each year, and that margin is shrinking further as advertisers walk back the DEI-linked commitments they made in 2020. That's the backdrop. It's not why we're asking.

The wider picture isn't any steadier. Newspaper ad revenue has fallen more than 80% since 2005, and local newsrooms are closing at a rate of roughly two a week nationwide. When outlets go under, it's rarely the ones built to center a Black perspective from the ground up that get to stick around.

We know a request for support isn't why you came here. But without readers choosing to fund this work directly, the depth of reporting we can do at home and abroad shrinks along with everyone else's. If you're not in a position to give, that doesn't change how much we value you as a reader.

If you are able to, a recurring contribution does more for us than a single one-time gift, because it lets us plan the next investigation instead of just the next invoice. It takes about 30 seconds, no long form, no account. Thank you for continuing to support independent journalism and freedom of the press.

Give once Give monthly Support another way

Related Stories

Back to top